NCM’s strategy is to develop the most advanced PET radiopharmaceutical manufacturing and distribution network in New York State. The American market for molecular imaging agents currently exceeds $1.3 billion annually and is expected to grow to over $3 billion by 2020.

Ali Abbasi,
President & CEO,



Tour our up and coming state-of-the-art manufacturing facility

The radionuclides employed for imaging purposes are isotopes of radioactive elements such as uranium or iodine that produce gamma rays with high penetrating power that can be recorded by a gamma camera or scintillation detector that captures the images..>

View a quick presentation of the science behind radio-pharmaceuticals.
461 Park Avenue South
New York, NY 10016

Office:  212-719-2322
Fax: (212) 997-4119


© NCM USA LLC 2011 All Rights Reserved   Home Contact us Investor Relations